Justin A Green Selected Research

tafenoquine

1/2022	Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
1/2020	Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
1/2019	Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
1/2019	Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
1/2019	Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers.
1/2019	Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
9/2017	Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.
1/2017	A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
12/2016	Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
3/2016	Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Justin A Green Research Topics

Disease

13	Vivax Malaria 01/2022 - 03/2014
7	Infections 01/2022 - 10/2007
4	Tuberculosis (Tuberculoses) 08/2013 - 10/2007
3	Granuloma 06/2010 - 01/2009
2	Body Weight (Weight, Body) 01/2022 - 12/2016
2	Glucosephosphate Dehydrogenase Deficiency 09/2017 - 12/2016
1	Vomiting 01/2022
1	COVID-19 12/2021
1	Parasitemia 01/2019
1	Hemolysis 09/2017
1	Fever (Fevers) 01/2017
1	Inflammation (Inflammations) 08/2013
1	Meningeal Tuberculosis (Tuberculous Meningitis) 09/2009
1	Central Nervous System Diseases (CNS Diseases) 09/2009
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 05/2009
1	Pulmonary Tuberculosis 05/2009
1	Central Nervous System Tuberculosis 01/2007

Drug/Important Bio-Agent (IBA)

14	tafenoquineIBA 01/2022 - 03/2014
6	Primaquine FDA Link 01/2019 - 02/2016
6	Matrix Metalloproteinases (MMPs)IBA 08/2013 - 01/2007
4	Chloroquine (Aralen)FDA LinkGeneric 01/2017 - 03/2014
3	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 01/2022 - 09/2017
3	Pharmaceutical PreparationsIBA 12/2016 - 05/2009
3	Conditioned Culture MediaIBA 05/2011 - 10/2007
2	p38 Mitogen-Activated Protein KinasesIBA 08/2013 - 05/2009
2	Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA 08/2013 - 05/2009
1	TabletsIBA 01/2022
1	ChAdOx1 nCoV-19IBA 12/2021
1	VaccinesIBA 12/2021
1	8-aminoquinolineIBA 09/2017
1	EnzymesIBA 09/2017
1	artenimol (dihydroartemisinin)IBA 12/2016
1	Lumefantrine Drug Combination Artemether (Coartem)FDA Link 12/2016
1	piperaquineIBA 12/2016
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 02/2016
1	Caspase 8 (Caspase-8)IBA 05/2011
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 05/2011
1	NF-kappa B (NF-kB)IBA 06/2010
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 06/2010
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2009
1	AcidsIBA 05/2009
1	Aminosalicylic Acid (Rezipas)FDA Link 05/2009
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 10/2007

Therapy/Procedure

5	Secondary Prevention 01/2022 - 03/2014
1	Therapeutics 01/2019